Seattle Genetics (NASDAQ:SGEN) Analyst Rating Consensus

Seattle Genetics (NASDAQ:SGEN) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2 by 11 Brokerage Firm. 5 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating. 5 Brokerage Firms have advised hold.

Other Equity analysts have also commented on the company shares. SunTrust Robinson Humphrey initiates coverage on Seattle Genetics (NASDAQ:SGEN). In the latest research report, SunTrust Robinson Humphrey announces the target price to $34 per share. According to the latest information available, the shares are now rated Neutral by the analysts at the agency. The rating by the firm was issued on March 3, 2016.

Seattle Genetics (NASDAQ:SGEN): 10 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $45.2 in Seattle Genetics (NASDAQ:SGEN). However, the stock price could fluctuate by $ 9.73 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $65 price target with the lower price estimate is calculated at $33

Seattle Genetics (NASDAQ:SGEN) witnessed a decline in the market cap on Tuesday as its shares dropped 1.79% or 0.7 points. After the session commenced at $39.13, the stock reached the higher end at $39.38 while it hit a low of $37.76. With the volume soaring to 841,328 shares, the last trade was called at $38.38. The company has a 52-week high of $52.3299. The company has a market cap of $5,380 million and there are 140,167,030 shares in outstanding. The 52-week low of the share price is $26.02.

Seattle Genetics, Inc. has lost 1.31% in the last five trading days and dropped 1.13% in the last 4 weeks. Seattle Genetics, Inc. is up 4.38% in the last 3-month period. Year-to-Date the stock performance stands at -14.48%.

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Companys marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology. In addition to ADCETRIS, the Companys pipeline includes six clinical-stage ADC programs consisting of SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. In addition, it has multiple preclinical and research-stage programs that employ its technologies. Its technologies include ADC technology and Seattle Genetics sugar-engineered antibody (SEA) technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *